Description

n-(3-Bromophenyl)-6-(2-[18F]Fluoroethoxy)-7-Methoxyquinazolin-4-Amine CAS NO 1389355-33-2 is a specialized fluorine-18 labeled quinazoline derivative, a critical compound in the development of Positron Emission Tomography (PET) radiopharmaceuticals. Its core value lies in its role as a precursor or intermediate for targeted molecular imaging agents, enabling non-invasive visualization and quantification of biological processes in vivo. This product is essential for pharmaceutical R&D teams, radiochemistry laboratories, and diagnostic imaging centers focused on oncology and neurology research, where precise targeting and high specific activity are paramount.

Application

• PET Radiopharmaceutical Precursor: Primary use as a key intermediate in the synthesis of novel fluorine-18 labeled PET tracers for cancer imaging.
• Oncology Research: Development of targeted imaging agents for specific receptors or enzymes overexpressed in various cancers, aiding in tumor detection and treatment monitoring.
• Neurological Disorder Studies: Potential application in creating tracers for imaging neurological targets, supporting research into Alzheimer's disease, Parkinson's disease, and other CNS conditions.
• Molecular Imaging Probe Development: Serves as a building block for research into new molecular imaging probes, facilitating drug discovery and development programs.
• Radiochemistry & Radiosynthesis: Used in specialized laboratories for the efficient, automated synthesis of clinical-grade PET radiopharmaceuticals under Good Manufacturing Practice (GMP) conditions.
• Preclinical Imaging: Enables the evaluation of biodistribution, pharmacokinetics, and target engagement in animal models during early-stage drug development.

Basic Information

Product Name	n-(3-Bromophenyl)-6-(2-[18F]Fluoroethoxy)-7-Methoxyquinazolin-4-Amine
CAS No.	1389355-33-2
Molecular Formula	C₁₇H₁₅BrFN₃O₂
Molecular Weight	392.22 g/mol
Synonyms	6-(2-[18F]Fluoroethoxy)-7-methoxy-N-(3-bromophenyl)quinazolin-4-amine; [18F]-Labeled Quinazoline Derivative; Fluorine-18 Labeled EGFR-TK Inhibitor Precursor; PET Tracer Intermediate 1389355-33-2; 4-[(3-Bromophenyl)amino]-6-(2-[18F]fluoroethoxy)-7-methoxyquinazoline; N-(3-Bromophenyl)-6-(2-([18F]fluoro)ethoxy)-7-methoxy-4-quinazolinamine
EINECS	Contact for details

Quality Control

This high-purity intermediate is manufactured and controlled under a strict quality management system suitable for radiopharmaceutical development. Each batch is supported by a comprehensive Certificate of Analysis (COA) detailing critical parameters such as chemical purity, radiochemical purity (where applicable), and specific activity. Our quality commitment aligns with the stringent requirements for materials used in drug development, ensuring reliability for your research and preclinical studies. Certificates of Analysis (COA) are available upon request.

Storage

Preserve in a tightly closed container, protected from light. Store at -20°C or below in a dedicated freezer. This compound is strictly light-sensitive (protect from all light exposure). For long-term storage, consider under an inert atmosphere to maximize stability. Allow the sealed vial to reach room temperature before opening to minimize moisture condensation.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Conforms to reference standard
Identification (MS)	Conforms to structure
Purity (HPLC)	≥ 95% (Chemical Purity)
Radiochemical Purity (TLC/HPLC)	≥ 98% (If supplied as labeled compound)
Specific Activity	Contact for details (Customizable, typically >1 Ci/µmol)
Solubility	Soluble in DMSO, DMF; sparingly soluble in ethanol

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.